Dr. Zhang on frontline treatment selection factors in metastatic kidney cancer

W. Kimryn Rathmell, MD, PhD, an internationally recognized expert in kidney cancer, is Chair of the Department of Medicine and Physician-in-Chief at Vanderbilt University Medical Center.

Data from the phase 2 LITESPARK-004 trial led to the FDA approval of belzutifan for patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma and other diseases.

The novel TKI zanzalintinib demonstrated early efficacy signals with manageable toxicity in patients with advanced clear-cell renal cell carcinoma.

Researchers are exploring the potential of CAR T-cell therapy in patients with renal cell carcinoma who have disease progression following treatment with checkpoint inhibitors and VEGF inhibitors.

Adjuvant pembrolizumab improved overall survival compared with placebo in patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

Data showed noninferiority of subcutaneous nivolumab to intravenous nivolumab in the time-average to nivolumab serum concentration over 28 days (Cavgd28) and the trough serum concentration at steady state (Cminss).